Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (June 2019)
22 slides from Qiagen's investor day presentation, Jun 20, 2019
Slide 1: 2019 Analyst & Investor Day: Molecular Diagnostics
2019 Analyst & Investor Day Molecular Diagnostics Disruptive portfolio focused on high-growth, high-demand opportunities Thierry Bernard Senior Vice President, Head of Molecular Diagnostics Business Area Sample to Insight
Slide 2: Disclaimer
Disclaimer Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All Regulation G: QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) statements other than statements of historical fact are, or may be deemed to be forward
Slide 3: Molecular Diagnostics market maintains status as fastest growing IVD sector
Molecular Diagnostics market maintains status as fastest growing IVD sector Our customers Total addressable market(1) Key trends • MDx dissemination: Acute to routine testing Growing demands for near-patient testing for QIAGEN market share: ~12% acute conditions combined with routine test consolidat
Slide 4: Disruptive portfolio focused on high-growth, high-demand opportunities
Disruptive portfolio focused on high-growth, high-demand opportunities Molecular Diagnostics sales trends Immune Response 2019-2023 target: ~+9-10% CER CAGR QuantiFERON technology for latent disease testing: #1 Expanding latent TB testing, Lyme disease test in development ~+5% CER CAGR ~$679 m ~$732
Slide 5: Strategy: Deliver above-market growth with disruptive portfolio, agility and partnerships
Strategy: Deliver above-market growth with disruptive portfolio, agility and partnerships Immune Response: Develop QuantiFERON (QFT) franchise and automated platforms 2023 target: >$400 million of QFT-TB sales, deliver QFT-Access and QFT-Lyme Focus on Infectious Diseases: Execute on launch opportuni
Slide 6: QIAGEN offers the most comprehensive and differentiated automation portfolio
QIAGEN offers the most comprehensive and differentiated automation portfolio 0 Pre-molecular assays Real-time PCR technology NGS technology Market potential >$0.2 billion with current menu >$1 billion >$2.7 billion >$0.3 billion >$0.8 billion (Clinical oncology) QuantiFERON NeuMoDx QIAsymphony GeneR
Slide 7: Immune Response: Broaden QuantiFERON menu and create new tests with partners
Immune Response: Broaden QuantiFERON menu and create new tests with partners Drive QFT-TB market conversion Launch QFT-Access in mid-2020 Expand DiaSorin menu: QFT-Lyme >$1 billion market opportunity: Leverage best-in-class automation partnership to drive market conversion of ~70 million annual late
Slide 8: QuantiFERON: Significant conversion potential from skin test to modern gold standard
QuantiFERON: Significant conversion potential from skin test to modern gold standard QuantiFERON-TB sales trends LTBI market only 18% penetrated QuantiFERON: ModernLTBI test gold standard QuantiFERON-TB Gold (4th generation) >$400 m Market opportunity: Can be fully automated $223 m >70 million annua
Slide 9: QuantiFERON: Developing complementary solutions to address global LTBI test demands
QuantiFERON: Developing complementary solutions to address global LTBI test demands QuantiFERON-TB Gold (QFT-TB Gold Plus) QuantiFERON-TB Access (QFT-Access) NEW Planning 2023 No continuous power No calibration or for sales goal: supply needed maintenance needed mid-2020 >$400 CE-IVD Option million
Slide 10: QuantiFERON: QFT-Lyme in development to address unmet needs
QuantiFERON: QFT-Lyme in development to address unmet needs Targeting potential $400-600 million market opportunity Rising occurrence of Lyme disease Confirmed cases Potential testing market 40.000 Planned Europe ~35,000 per year ~12-14 million tests per year CE-IVD launch in U.S. ~30,000 per year ~
Slide 11: Infectious Diseases: Expand PCR test portfolio with next generation of microfluidic systems
Infectious Diseases: Expand PCR test portfolio with next generation of microfluidic systems Roll out QIAstat-Dx and NeuMoDx Develop deep test menu Ensure flawless launch of new infectious disease testing platforms Develop a critical mass of infectious disease tests in key focus areas Blood-borne vir
Slide 12: Infectious Diseases: Next generation of systems addressing urgent customer needs
Infectious Diseases: Next generation of systems addressing urgent customer needs Core / Hospital laboratories Near-patient clinical laboratories 2019 market opportunity 2019 market opportunity ~$2.7 billion ~$800 million ~+7-9% annual CAGR Hospital and Community hospitals and ~+20-25% annual CAGR re
Slide 13: NeuMoDx: Simplest, fastest next generation of clinical PCR testing
NeuMoDx: Simplest, fastest next generation of clinical PCR testing Two platforms with identical consumables and technology PCR chamber Microplate format DNA / RNA capture chamber 12 sample ports 12 PCR ports NeuMoDx 96 NeuMoDx 288 Select European test menu expansion plans Specification NeuMoDx N288
Slide 14: QIAstat-Dx: Next generation of syndromic testing
QIAstat-Dx: Next generation of syndromic testing Breakthrough system based on microfluidic technologies Results in All-in-one mini-lab about one hour provides one-step process Exclusive dry Both wet and dry swab protocol reagents on board Room temperature Up to 48 plex using storage real-time PCR QI
Slide 15: Oncology and Precision Medicine: Extending our leadership for molecular CDx solutions
Oncology and Precision Medicine: Extending our leadership for molecular CDx solutions Deepen pharma partnerships Strengthen PCR / NGS offering Leverage leading bioinformatics >25 pharma co-development master Only supplier of full molecular CDx portfolio Drive growth with leading solutions collaborat
Slide 16: Oncology and Precision Medicine: Partner of choice for molecular CDx solutions
Oncology and Precision Medicine: Partner of choice for molecular CDx solutions Precision medicine molecular testing overview Selected pharma co-development CDx partners Requirements: • Access to PCR and NGS technologies • Full automation 2019 market opportunity • Throughput and ~$1.1 billion workflo
Slide 17: Oncology and Precision Medicine: GeneReader NGS System complete workflow solution
Oncology and Precision Medicine: GeneReader NGS System complete workflow solution Integrating top performing chemistry with best-in-class bioinformatics analysis and interpretation Proprietary QIAGEN chemistry 3 x 3 GB flowcells QCI-Interpret Selected Research Use Only assay menu GeneReader Comp. I
Slide 18: LDT Workflow Solutions: Addressing demands for high-quality assay components
LDT Workflow Solutions: Addressing demands for high-quality assay components Drive QIAsymphony placements Grow sales of LDT solutions Expand QIAsymphony portfolio >3,300 >2,500 >1,500 2015 2019 goal 2023 goal On track to achieve >2,500 cumulative Enhance portfolio for LDT processing in New applicati
Slide 19: Summary
Summary • Disruptive portfolio focused on high-growth, high-demand areas of MDx • Expanding QuantiFERON with automation partners, new Lyme assay • Executing on launch of differentiated platforms to capture large opportunities • Addressing clinical lab testing needs with sample technologies and LDTs
Slide 20: Appendix
Appendix ‘Sample to Insight
Slide 21: NeuMoDx: A disruptive integrated PCR testing platform in a $2.7 billion market opportunity
NeuMoDx: A disruptive integrated PCR testing platform in a $2.7 billion market opportunity Competitive benchmarking Cobas 6800 Panther Beckman Veris NeuMoDx 288 NeuMoDx 96 Panther (+ Omni LDT Cobas 8800 Alinity M Fusion (Discontinued) channel) Volume in '00,000s cm3 38 16 18 27 81 120 38 48 On-board
Slide 22: QIAstat-Dx: Novel syndromic testing system entering an $800 million market opportunity
QIAstat-Dx: Novel syndromic testing system entering an $800 million market opportunity Competitive benchmarking QIAstat-Dx Biofire FilmArray Biofire Torch ePlex Verigene (4 scalable slots (1 slot) (12 slots) (12 slots) (1 slot) used for comparison) Throughput (in 8 hours) 28 9 108 60 4 Throughput pe